Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SMCE made it on Youtube after close around 4pm
I don’t think link works
$SMCE Portfolio Bank stocks include VEEV $201.77 GOOGL $171.16 JD $31.95 BABA $78.46 IMMR $7.51 NVDA $904.12 EA $125.24 META $472.60 ADBE $488.10 QCOM $ 180.55 AAPL $182.74 MSFT $ $410.54 BIDU $109.60
— Brian Sowa (@sowa32214) May 8, 2024
AI Fintechhttps://t.co/uMe4wrgZAz
SMCE is getting interesting again
Today it is moving and it was not me buying today.
May be something to watch
Guys what you think about RDGL (Biotek) and TDRK ( solid reverse merger)
I used to love DLOC and i was heavily invested and i am only light💡ly invested in DLOC with free shares. You are correct if Satenna gets completed and works DLOC should run but as far as i know they only patented/trademarked the name and none of us have seen or heard of the actual completed product. I hope they can get it done. My DLOC shares are set at a leave it and forget it 99 cent sell if they pull it off.
I am heavily invested in AFFU and it is starting to get noticed. It is possible the merger or mergers are almost complete with highly successful people with technological needed services.
News should be coming out sooner or later.
DLOC is trying to connect people to the internet with smartphones from Satellites.
AFFU mergers will be making sure companies stay connected to internet and cloud services by Connectivity. Connectivity is going to be a huge business making sure companies internet services are staying up and running
As far as RS a couple other companies are doing them to FDCT GSPT JAGX that i know of.
….i of course like IGPK but its confusing w RS coming and late filings so its still a ?? when there should already be clarity 4 months later ….and i like DLOC if they ever can actually come out with Satenna……changes everything….but that may never happen ….but its a def huge radar as if they can pull it off……booooooom!
$ATNM up $1 this morning
$IDKFF $IQST $EMED
Anything news worth looking into?
I am holding a bunch of different ones but always looking for the next quiet hidden gem
I agree with you about the switch definitely getting turned off since the 2nd half of 2021 and remaining this way for the last few years.
We are definitely seeing signs that the OTC is trying to come back to life again. 2023 was the first decent year we have seen in a while with you even calling a couple of 1,000% runners.
There are a few I got my eye on, and I especially like JAGX which is a beaten down NASDAQ stock here with expected phase III results along with an OS around 50 million.
If these results are good this could cause and VTYX type of move we seen today.
I Hope all is well with you my friend!
Good stock RSPI….but ‘They’ turned the switch on the OTC for about one month last November……and many stocks ran like old times…..then the switch was turned off ….its that clear to me.
Literally like a light switch……last November before this there were fewer people then ever posting or participating in OTC …after two of worst years ever…..thats why the switch analogy is i think true. Its the algorithm's and AI bots….and illegal probable off shore and on shore lol MM activity….but nothing has ever been the same since 2021….and that one month of November.
The powers that be……well…..we dont really have a free market…..so many biotechs like that would have run to a penny 2001 to 2021….but not now.
Who is looking out for OTC corruption? No one.
The IRS though may of all entities help…..they will see the free money out of thin air that was made by millions in 2021 and before, and all those capital gains……by trading OTC….and then they will see the losses and probably 95% less taxes they are getting in capital gains since 2021….maybe they will force the switch back on?
Drug Companies making Epilepsy medication
MRNS $10.08
CERE $43.16
STOK $4.98
UCBJF $102.00
SNY $45.63
PFE $27.00
OTSUK $18.36
RespireRx Pharmaceuticals Ticker: RSPI .0012 x .0014
Market cap $613,263
Is working on Revolutionary New Hope:
KRM-II-81 Drug-Resistant Epilepsy Patients
Link found on National Library of Medicine
The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders
https://pubmed.ncbi.nlm.nih.gov/35041859/
https://www.neurexplain.com/2024/01/17/revolutionary-krm-ii-81-a-new-hope-for-drug-resistant-epilepsy-patients/
National Institutes of Health
A clinical case of a 19-year-old male patient with pharmacoresistant seizures occurring following parieto-occipital tumor-resection at age 6 ...
KRM–II–81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10784158/
RSPI @ .0012 Looking really nice with a decent share structure. They have been putting out some very nice news lately as well:
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine
Glen Rock, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that KRM-II-81, its lead GABAA receptor potentiator (GABAkine), has advanced to the next level of evaluation within the NIH HEAL Initiative® Preclinical Screening Platform for Pain (PSPP) program.
The Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management. For more information, visit: https://heal.nih.gov.
The PSPP program, part of the NIH HEAL Initiative, evaluates non-opioid assets in a battery of established preclinical pain models. The PSPP program accepts small molecules, biologics, devices, or natural products for evaluation, from researchers in academia and industry worldwide. For more information, visit: https://heal.nih.gov/research/preclinical-translational/screening-platform.
Emerging data showed that KRM-II-81 blocked pain-like behaviors in rats at doses with minimal or no detectable side effects. These observations were made with both male and female rats in two measures each, in models of post-incision pain and spinal nerve ligation-induced persistent neuropathic pain. These research findings support prior observations by our and other laboratories that KRM-II-81 is effective in relieving acute, chronic, and neuropathic pain in a number of models without tolerance development or sedation. These data trigger the advancement of KRM-II-81 within the NIH PSPP program where additional disease-specific pain models will be evaluated.
Dr. Jeffrey M. Witkin, a Senior Research Fellow with the Company said that “we are excited to see the robust anti-pain efficacy of KRM-II-81, knowing the urgent need for non-opioid pain therapeutics. We continue to be impressed by the comparative ‘therapeutic index’ of this compound that we had predicted from earlier research.”
Dr. Lippa added, “We are all very excited about developing KRM-II-81 and expanding the IND enabling studies so as to begin human studies. Pending clinical validation, we believe that KRM-II-81 has the potential to represent a breakthrough medication for pain, epilepsy, and other neuropsychiatric disorders.”
The RespireRx team is led by Dr. Arnold Lippa, RespireRx Executive Chairman, Interim Chief Executive Officer, Interim President and Chief Scientific Officer along with RespireRx Senior Research Fellows, Drs. Jeffrey M. Witkin and Rok Cerne and collaborator, Dr. James M. Cook, in addition to their academic affiliations at Ascension St. Vincent and Indiana University/Purdue University and the University of Wisconsin-Milwaukee, respectively. The team has extensive expertise in drug discovery and development including the development of novel analgesic drugs and an extensive publication record with a combined total of over 1,000 scientific publications. The team has already profiled the activity of KRM-II-81 in a broad range of preclinical studies where it has displayed a high degree of analgesic activity and is excited at the prospect of advancing the Company’s lead GABAkine toward clinical development. In cellular studies, KRM-II-81 preferentially bound to specific subtypes of GABAA receptors and boosted the ability of GABA to inhibit pain sensory neurons in the spinal dorsal root ganglia. In intact animal models of acute and chronic pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression, or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
Unrelated to the NINDS project, KRM-II-81 has also shown very promising results in multiple animal models of treatment resistant epilepsy and in human translational studies where it reduced epileptiform electrical signaling in brain tissue removed from treatment resistant epileptic patients who underwent surgery.
About RespireRx Group
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units (“RespireRx Group”) are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors.
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has in-licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific, subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant animal models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment-resistant epileptic patients who underwent surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
ResolutionRx: Pharmaceutical Cannabinoids.
ResolutionRx Ltd (Australian Company Number a/k/a ACN 664 925 651) was formed in Australia on January 11, 2023 by RespireRx as an unlisted public company. RespireRx has contributed by sublicense and license with ResolutionRx, its sleep apnea drug development program subject to certain liabilities. ResolutionRx will now engage in the research and development (“R&D”) associated with that program, initially for the development of a new formulation of dronabinol for use in a Phase 3 clinical trial and the filing of regulatory approval for the treatment of obstructive sleep apnea (“OSA”). The current total budget for that program over the next several years is approximately US$16.5 million, most, but not all of which is expected to be eligible for the Australian R&D Tax Incentive (“RDTI”). Dronabinol, an endocannabinoid receptor agonist, has already demonstrated significant improvement in the symptoms of OSA in two Phase 2 clinical trials. OSA is a serious respiratory disorder that impacts an estimated 90 million people in the United States, Australia, the United Kingdom and Germany and that has been linked to increased risk for hypertension, heart failure, depression, and diabetes. There are no approved drug treatments for OSA.
Because dronabinol is already FDA approved for the treatment of AIDS related anorexia and chemotherapy induced nausea and vomiting, RespireRx and ResolutionRx further believe that its repurposing strategy would only require, in the United States, approval by the FDA of a 505(b)(2) new drug application (“NDA”), an efficient regulatory pathway that allows the use of publicly available data.
Additional information about RespireRx and the matters discussed herein can be obtained on the RespireRx website at www.RespireRx.com or RespireRx’s filings with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov. Additional information about ResolutionRx and the matters discussed herein can be obtained on the ResolutionRx website at https://www.resolutionrx.com.au.
Not a Securities Offering or Solicitation
This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sales of securities in any jurisdiction in which such offer, solicitation or sale of securities would be unlawful before registration or qualification under the laws of such jurisdiction.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Company intends that such forward-looking statements be subject to the safe harbor created thereby. These might include statements regarding the Company’s future plans, targets, estimates, assumptions, financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about research and development efforts, including, but not limited to, preclinical and clinical research design, execution, timing, costs and results, future product demand, supply, manufacturing, costs, marketing and pricing factors.
In some cases, forward-looking statements may be identified by words including “assumes,” “could,” “ongoing,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” “anticipates,” “believes,” “intends,” “estimates,” “expects,” “plans,” “contemplates,” “targets,” “continues,” “budgets,” “may,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words, and such statements may include, but are not limited to, statements regarding (i) future research plans, expenditures and results, (ii) potential collaborative arrangements, (iii) the potential utility of the Company’s product candidates, (iv) reorganization plans, and (v) the need for, and availability of, additional financing. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release.
These factors include but are not limited to, regulatory policies or changes thereto, available cash, research and development results, issuance of patents, competition from other similar businesses, interest of third parties in collaborations with us, and market and general economic factors, and other risk factors disclosed in “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC on April 17, 2023 (the “2022 Form 10-K”).
You should read these risk factors and the other cautionary statements made in the Company’s filings as being applicable to all related forward-looking statements wherever they appear in this press release. We cannot assure you that the forward-looking statements in this press release will prove to be accurate and therefore current and prospective investors, as well as current and potential collaborators and other current and potential stakeholders, are encouraged not to place undue reliance on forward-looking statements. You should read this press release completely. Other than as required by law, we undertake no obligation to update or revise these forward-looking statements, even though our situation may change in the future.
We caution current and prospective investors, as well as current and potential collaborators and other current and potential stakeholders, not to place undue reliance on any forward-looking statement that speaks only as of the date made and to recognize that forward-looking statements are predictions of future results, which may not occur as anticipated. Actual results could differ materially from those anticipated in the forward-looking statements and from historical results, due to the risks and uncertainties described in the 2022 Form 10-K, in our quarterly reports on Form 10-Q, in our Current Reports on Form 8-K, and other reports that we file with or furnish to the SEC and in this press release, as well as others that we may consider immaterial or do not anticipate at this time. These forward-looking statements are based on assumptions regarding the Company’s business and technology, which involve judgments with respect to, among other things, future scientific, economic, regulatory and competitive conditions, collaborations with third parties, and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. Our expectations reflected in our forward-looking statements can be affected by inaccurate assumptions that we might make or by known or unknown risks and uncertainties, including those described in the 2022 Form 10-K, in our quarterly reports on Form 10-Q, in our Current Reports on Form 8-K, and other reports that we file with or furnish to the SEC and in this press release. These risks and uncertainties are not exclusive and further information concerning us and our business, including factors that potentially could materially affect our financial results or condition, may emerge from time to time. For more information about the risks and uncertainties the Company faces, see “Item 1A. Risk Factors” in our 2022 Form 10-K. Forward-looking statements speak only as of the date they are made. The Company does not undertake and specifically declines any obligation to update any forward-looking statements or to publicly announce the results of any revisions to any statements to reflect new information or future events or developments. We advise current and prospective investors, as well as current and potential collaborators and other current and potential stakeholders, to consult any further disclosures we may make on related subjects in our annual reports on Form 10-K and other reports that we file with or furnish to the SEC including but not limited to our most recent Form 10-Q as of September 30, 2023 filed with the SEC on November 17, 2023.
Company Contact:
Jeff Margolis
RespireRx Pharmaceuticals Inc.
126 Valley Road, Suite C
Glen Rock, NJ 07452
Senior Vice President, Chief Financial Officer, Treasurer and Secretary
Telephone: 917-834-7206
Email: jmargolis@respirerx.com
www.respirerx.com
https://www.globenewswire.com/newsroom/ti?nf=OTAzNjMxMSM2MDY4MTEwIzIwMjAzNzc=
https://ml.globenewswire.com/media/NTNmNGZhZDQtNDNhMy00MzhhLTk2ZTctOTRhNjVlMDIyZjFhLTEwMzE5NDk=/tiny/RespireRX-Pharmaceuticals-Inc-.png
Source: RespireRX Pharmaceuticals Inc.
© 2024 GlobeNewswire, Inc.
https://www.otcmarkets.com/stock/RSPI/news/story?e&id=2765667
Bullish
BULLISH
Five 2021, Zero 2022 and Two 2023 1,000% runners:
—-but i had more bad picks then ever last two years during the OTC SEC winter….lets see if we can get market back to normalcy…..doesnt the government want our capital gains tax money from the virtual thin air? Thats a win win lol……I paid one million in 2020/2021 in State and Fed taxes all from penny stocks…then nothing cause lost lost and lost alot in 2022 and 2023….
2021:
CCTL .004 to .04+
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160769749
VPER .0013 to .04+
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161166405
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160862088
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161181081
DSCR .003 to .03+
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161220721
APYP .007 to .10+
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161899497
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161902047
GGII .01 to .10+
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163522704
Then 2023 both my 1,000% runners on one post:
JohnnyRothrock
Member Level
Re: DTGoody post# 389
Monday, October 30, 2023 12:16:33 PM
Post# of 422 Go
…hey brotha….maybe OTC waking up a bit? I like:
SONG and BEGI.
SONG has massive revs for a penny stock and CEO is doing everything right lately:
Condemning pro-Hamas rallies on American college campuses by increasing their music royalty fees up millions….to those campuses where the rallies are…..and just that PR last Friday so bold……first public company to do this?
And for DD i found PennyWhale on Twitter has real good DD..check it out.:
https://twitter.com/WhalePenny
Price is now .0012 but i called it on BBs board Friday at .0008…
i wanted to see if something would run more then a day to post here, lol
The second stock that really has my interest is @.0011 now……: BEGI. They said a Patent should be issued in November in regards to technology trading software/platform that gives them next 20 years protection for trading stocks on blockchain…..which isnt this a yuuuge deal? With GVSI a blockchain rumored RM coming up …now running wild……i think The Market will look for any legit other micro penny stocks in the field….and then they will find with wide eyes BEGI.
So i need to do more DD on BEGI but got a good starter and looking to buy any shares under .001 if possible.
Ok thats it lets see if OTC wakes up and we can all have fun again!
Two 1,000% gainers for 2023:
BEGI .0011 to .125
SONG .0008 to .01
Both predictions on same day and same post…so pretty easy this year. Penny market been horrible for me and most people over 2 years now so that was needed…..but lets see what 2024 has in store for us….:
JohnnyRothrock
Member Level
Re: DTGoody post# 389
Monday, October 30, 2023 12:16:33 PM
Post# of 422 Go
…hey brotha….maybe OTC waking up a bit? I like:
SONG and BEGI.
SONG has massive revs for a penny stock and CEO is doing everything right lately:
Condemning pro-Hamas rallies on American college campuses by increasing their music royalty fees up millions….to those campuses where the rallies are…..and just that PR last Friday so bold……first public company to do this?
And for DD i found PennyWhale on Twitter has real good DD..check it out.:
https://twitter.com/WhalePenny
Price is now .0012 but i called it on BBs board Friday at .0008…
i wanted to see if something would run more then a day to post here, lol
The second stock that really has my interest is @.0011 now……: BEGI. They said a Patent should be issued in November in regards to technology trading software/platform that gives them next 20 years protection for trading stocks on blockchain…..which isnt this a yuuuge deal? With GVSI a blockchain rumored RM coming up …now running wild……i think The Market will look for any legit other micro penny stocks in the field….and then they will find with wide eyes BEGI.
So i need to do more DD on BEGI but got a good starter and looking to buy any shares under .001 if possible.
Ok thats it lets see if OTC wakes up and we can all have fun again!
….IGPK merge w billion dolla’ JFH….if not in buying a mil or so just in case it all comes together…might be a wise thing to do….depending on your risk tolerance…already has merged but awaiting the new company getting access to OTC and filings…… but its moving now…..this has the ultimate IT factor being such a large and quickly growing company in China now wanting to list here in U.S…….
If i didnt have shares and didnt believe or want to believe the DD….i would still buy a few hundred thousand while under .007 just in case …its .0052 right now….…cause if it checks out perhaps biggest merge in OTC history. Even if 10% merges in would be hundreds of millions….and we can all see their company, app, products and videos on twitter for weeks now.
Lets see how it goes……getting crazy now though woo!
Check out AFFU which owns OneMindNg
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173562477
Partnerships with major companies like
Dell
Nvidia
Orange Business
And others
I added to my AFFU which doesn't trade much and all of the sudden 1,800,000 showed up for a lot less.
It looks like new shares are hitting the market or a large holder is selling for tax loss.
Caution on the stock at this time. I like the OneMind partnerships but the market is killing it.
AFFU is OneMind working with Dell
Awesome enjoy !!!
RMRK! Thank you. I will try for a million on Monday. I'm in Jamaica right now.
lol nice!….and just like that for last two weeks ‘they’ turned off switch to OTC…but today not bad…..also i think most are simply buying. Christmas presents so not as much money to go round….if this is true starting next week huge volume again could return….
And bro i like : RMRK @.001 can be bought right now……..DD Dempsey did all the DD lol so this is easy pick….basically huge RM i really like, as it is a novel way to harvest Omega oils instead of expensive and harmful big fish needed to be caught….just grow ‘unlimited’ cheap algae …and the RM will give them this new biz that Universities in Australia been working with…..also they have a fertilizer from algae with many many many benefits over traditional……huge markets …2 huge markets with completed RM that RMRK can truly Disrupt.
Oh…no notes or convertibles in filings toowooohooooo lol…here is the awesome DD thanks DD DEMPSEY!::
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172358096
Thank You! And I got to change my signature as I was replying to that clown Huggy Bear! LOL
..hey its Bitcoin-mania again: CGAC .@.0003: is a strong buy as its cheapest Bitcoin stock in the entire market that really mines bitcoin …at least that i can find.
So the downside small upside huge.
But SS is big - 4 bil OS and 10 bil AS….so i understand if you dont, or anyone buy. Me? Buying big cause the CEO the last 3 weeks been tweeting about all these new bitcoin mining computers….get this….1,000 are being purchased (!) with …after last nites new tweet from CEO….722 now purchased with 560 online NOW wooohooo!
Anyways check out his tweets, what i like is i found this most important info of the 722 purchased so far and 560 online when i followed the tweet thread where CEO Logan answered this guy…..and only 40 other people have viewed it unlike the main tweet hundreds….anyways check it all out…..bitcoin mania is here i think for awhile as the bitcoin halving event happens in three months or so !:
Logan William Rice
@thenew_cgac
$CGAC - In the bull run, CGAC continues to add to its fleet; $CGAC has purchased another 41 XP 134TH/S miners. Onward and upward.
9:23 PM · Dec 5, 2023
·
685
Views
getmoreshares
@getmoreshares
now there are 722 miners?
9:58 PM · Dec 5, 2023
·
34
Views
Logan William Rice
@thenew_cgac
·
10h
That is correct. 560 online, Remaining purchased and awaiting hashing.
…these tweets were big follow up tweets from November 15th:
Logan William Rice
@thenew_cgac
$CGAC - The purchase of the miners is going well; the company has acquired 121 miners thus far in the process of purchasing the 1,000 miners. I will keep updating as more miners come into the $CGAC fleet. Code Green Apparel Corp.'s mining fleet is currently at 681.
11:26 AM · Nov 15, 2023
·
7,193
Views
https://twitter.com/thenew_cgac
Description of Antminer S19 XP 134Th/s
You can buy now ASIC crypto miner model Antminer S19 XP 134 Th/s from Bitmain, mining SHA-256 algorithm with a maximum hashrate of 134Th/s and power consumption of 3010W.
Coins that can be mined with this ASIC miner: Bitcoin (BTC), Bitcoin Cash (BCH), and Bitcoin SV (BSV), other SHA-256 coins.
https://www.theminingfuture.com/miners/item/bitcoin-miners/bitmain/antminer-s19-xp-134th/
Hey i thought being a novel biotech that would have run too! …but i got another one gonna release here soon still doing dd its the cheapest bitcoin actual miner in the markets….
RSPI is by far my worst call of the year. I got crushed on this one too. I broke my own rule of never chasing a stock and bought this at the open yesterday morning at .003. When I seen the price break down further than just retail profit taking I took a look at the most recent 10-Q. They have a ton of convertible debt.
Sorry for bringing RSPI to the board here. The guy who did the video on it usually makes pretty good calls, but I guess he didn't look at the financials before making his video on it.
On to the next one my friend.
With your track record you are allowed to make a bad call every now and then. BEGI hit 1000% from your initial call and SONG was close to 1,000% LOL
So no worries my friend.
RSPI Traded over 100 million shares yesterday and doubled in price. Today there was a lot of profit taking. I am definitely not discounting this stock as there appears to be a lot going on with this stock. The guy who does these videos is pretty good with his calls. When these phase III trials are announced I believe this will be the next penny runner as well.
…yeah lets see what December brings, and man BBRW i wont mention again…will not support a company that i think is so recklessly diluting…..what a shame! Bad call…..so far…
Nice it's moving out the gate! WHSI
Check out $RSPI This Biotech Company is Massively Undervalued and Developing the Next Breakthrough Treatment:
$WHSI: ‘Help! Stock-has-Fallen!: Can it get up?”:
lol
…at end of day, many people remember these commercials so 1/2 the work and attention to The Market at large is done for WHSI and their soon to be released iHelpMax that is a very important product that can literally help people or even save their lives. So im a buyer w a starter see what happens…w this good SS i think this could be another big Christmas rally stock into New Year….::
PPS is @ .0007
AS 3 bil
OS 1.7 bil
Tradeable Float around 700 mil
….(an excellent goldilocks SS for a big run as long as they dont kill it with dilution)….
..in a couple weeks in the summer, WHSI got their new iHelpMax..three key wireless government certificates needed if it was ever gonna come to market…two in the United States and one in Canada:
Wearable Health Solutions Secures FCC Certification for Senior Device, Paving the Way for Production, Marketing, and Sales
Press Release | 07/28/2023
Wearable Health Solutions' iHelp MAX (XWI-EC4WHS) Receives Prestigious PTCRB Certification, Securing Its Place Among Top-Performing Cellular Devices
Press Release | 07/31/2023
Wearable Health Solutions Inc.'s iHelp MAX Receives Approval from Industry Canada/IESD
Press Release | 08/03/2023
…at this same time they also PR’d debt relief, which is always good to see if a stock has a chance to run in future:
Wearable Health Solutions, Inc. Settles $633,000 Legacy Debt at Significant Discount, Bolsters Financial Position for Future Growth
Press Release | 08/02/2023
https://www.otcmarkets.com/stock/WHSI/news
Then, they announced in weeks after, that they are partnering with two AI companies in New York: NextRealmAI and AI Venturtech…both these companies are just starting to tweet about WHSI on their twitter pages…the pending ‘Investor Roadmap’, and Venture Capitalist meetings sound particularly bullish and promising:
NextRealm AI
@nextrealm_ai
After some delay, we are ready to push forward with Wearable Health Solutions $WHSI in promoting them as key integrator of generative AI into their digital health platform
#ChatGPT4
#IBM
Exciting future for $WHSI!
#ArtificialInteligence #NLP
1:11 PM · Nov 14, 2023
https://twitter.com/nextrealm_ai
and:
AI Venturetech
@aiventuretech
·
Nov 15
Data is the new oil, and Wearable Health Solutions $WHSI is a health data producer.
Shareholder roadmap pending
Market cap: $1.2 million
https://otcmarkets.com/stock/whsi/quote…
#healthcare #IoT #artificialintelliegence #generativeAI #ChatGPT4 #Huggingface #IBM
AI Venturetech
@aiventuretech
Nov 21
Great meeting at NYC Global Deeptech conference at #Columbia
Networked with number of #VC managers, and assisted Wearable Health Solutions $WHSI with introductions
#NYC #ArtificialInteligence #health #deeptech
https://twitter.com/aiventuretech
…then the big news….basically their new iHelpMax4G that just got all those above government wireless approvals over the summer, is now being produced for a pilot program….for a full scale mass launch soon after:
Wearable Health Solutions (WHSI) is Ready to Produce iHelp Max 4G: A Next-Generation Mobile Medical Alert Device with 4G Connectivity, Fall Detection, and Geo-Fencing, Specially Designed for Senior Citizens
Press Release | 10/10/2023
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Wearable Health Solutions (OTCMKTS: WHSI), a publicly-traded health-tech company, is prepared to begin production of its latest innovation, the iHelp Max 4G. This mobile medical alert system is designed for the safety and connectivity of its users, with a primary focus on the elderly, physically disabled individuals, and those who live alone, both in their homes and while on the move.
Within the next 30 days, the company is set to begin pilot production of the latest version of iHelp Max. After this critical phase, units will be sent to direct consumers, and both domestic and international wholesale dealers. Mass production and marketing will commence thereafter.
Key features that distinguish it include:
* Voice-Activated Assistance: Seamless integration with virtual assistants allows for hands-free operation.
* Telehealth Ready: Real-time sharing of vital signs such as blood pressure, oxygen levels, and temperature via Bluetooth.
* Geo-Fencing: Instant alerts for entering or exiting predetermined areas, providing an additional layer of security.
* Fall Detection: Automatic notification to a trained operator without pressing the SOS button, ensuring immediate assistance.
* Crystal Clear Audio: Loud and adjustable audio control with a 2-way speaker for clear communication.
* Visual and Audio Battery Strength Indicator: The device notifies the wearer and their circle of care when the battery is low.
* Water and Shatter Resistant: Built to withstand everyday wear and tear, including water exposure up to IP67 standards.
* Lightweight and Compact: Weighing just 2 ounces and measuring 2.8" x 2.1" x .8", it's designed for comfort and convenience.
* Multiple languages: configurations.
SO: goldilocks SS not too big not too small so many thousands could trade stock and get involved….debt reduction, two key AI partnerships both starting to tweet about WHSI…..and their premier product hears in development got all its wireless licenses from U.S. and Canada and said right now in pilot program with mass production sales soon after:
Its all coming together for WHSI right now. These then are the times to consider taking a position to me……or if skiddish out there, maybe just wait for big volume of over 50 mil in a day and .001 break before jumping in?
What i really like:: Its a known consumer product for 40 years ‘Ive fallen and cant get up!’ commercials everyone used to know…..so awarness is all thats needed and people may remember, and buy-buy-buy like Jim Cramer honking horns lol…….
…also, its an A.I. play and its still in trip Z on verge of perhaps a major sales push of their new iHelp4GMax…….yeah..im a buyer and see if The Market likes whats going on as well…..as this has a great story, SS, A.I, and new product coming out…that makes this a possible 2023 Christmas runner in this new hot OTC we all find ourselves in!
Thank You! I will definitely check it out!
Thanks! …and i think BBRW could go 1,000% from .0002….if they dont dilute a ton ..even if i get shares today at .0003 i think .003 could happen. Dilution has been terrible so it could collapse… but idk to believe it but someone on board said dilution will end …end of year…though another billion could easily be diluted so i could lose or break even here.
Anyways…..they have record deals and revs in Q4 right now….and in new year getting into European market…..and hey they a tually sold equipment to my fav brewery Sierra Nevada i handle this brand at work.
So: BBRW lets see what happen s. ut im buying a good starter ‘dis cheap …here is October PR that is really good…..1.7 bil OS AS is horrible…..but it has a chance….to run:
GRASS VALLEY, CA, Oct. 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Today BrewBilt Manufacturing Inc. (the "Company") (OTCPINK: BBRW) announces that the company recently delivered $400,000 in brewery orders, and has received approximately $1.5M in new orders for the 4thQTR.
Jef Lewis, Chairman & CEO, stated, “Due to supply chain problems, we experienced delays in production during the first 6 months of 2023. We are pushing hard with our manufacturing and fabrication, and should be back on track the first QTR of 2024.”
The company recently delivered or is within a week of delivery for brewery systems to Narrative Fermentations in the California Bay Area, Alibi Ale Works in Lake Tahoe, Nevada, Tirrito Farm in Wilcox Arizona, and Tallman Brewing in Oregon in value of $400,000.
The company has new production schedules with Russian River Brewing Company in Santa Rosa, California, Uncle Charlie's Firehouse & Brew in Folsom, California, Ravenna Brewing in Seattle, Washington, and Pine Star Brewing in Loomis, California; in value of $1.5M.
Jef Lewis further stated, “I want to thank our shareholders, our service providers and our customers for their patience and support. BrewBilt will end the 2023 year with its highest revenue, and 2024 will be our breakout year as we enter Europe and gain traction in the USA.”
BrewBilt Manufacturing has fabricated brewery systems for large major craft breweries in the USA such as Sierra Nevada Brewing Company and Russian River Brewing Company. We are proud to have been chosen by these successful breweries to be a part of their craft beer production.
Sierra Nevada Brewing Co. is worth an estimated $1.2 billion. This makes it the sixth most valuable brewery in the U. S. and the 23rd most valuable alcohol brand in the world. Sierra Nevada Brewing Co. was established in 1979 by home-brewers Ken Grossman and Paul Camusi in Chico, California, United States.[1] The brewery produced 786,000 US bbl (922,000 hl) in 2010,[2] and as of 2016, Sierra Nevada Brewing is the seventh-largest brewing company in the United States and is the third largest privately owned brewery in the United States.
Looks like BEGI is going to be your 1st 1,000% for 2023. You called it on BB's Board at .0008 and today it hit .01!!! You know what drives these stocks and that Block Chain News was the ticket that you correctly called my friend! Congratulations on BEGI!!!
I just want to puke for missing this my friend. I honestly went on the board and seen all of the bashing and the share structure scared me off.
I am happy for you though and I hope this is the start to a better market ahead.
Keep your eye on ZHUD. This is a custodian play with a pending a Reverse Merger.
The Custodian ship just got awarded to Belisarian Holdings:
https://belisarianholdings.com/updates
It just went pink current from E.M.
160 million OS. Reduced by over 240 million shares.
No Notes or Convertibles.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173132919
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173244169
Zhuding International Limited is now Pink Current. Pink Current reporting enables us to restore shareholder value, a goal we have been working diligently to achieve. $ZHUD
— Belisarian Holdings (@BelisarianCusto) November 7, 2023
Thanks Bud, I wish it was up 300%, but it's still right around the same price of .009. I Would love to see some more follow up news on it.
Great call DTGoody! : KRTL up almost 300% from your post the other day wow!
…thanks will check it out!
KRTL .0095 News Coming Tomorrow according to Tweet. This has a 37 million share Float:
$KRTL, PR scheduled for Tomorrow.
— KRTLBIOTECH OTC:KRTL (@KRTLBiotech) November 14, 2023
….ZERO 1,0000% gainers in 2022: complete shut out. OTC was i thought maybe this time, dead for good after SEC regulations.
Now….who know? Maybe it was all for the better?
But not too shabby …. since 2017 i was fortunate to pick 24 penny stocks that ran 1,000% or more. Some way more like ENZC my best all time. Ive tried to give good and real reasons why these stocks could run……..ive probably called about 20 or so bad stocks on this board in this time that either did nothing or lost money. Also though, ive called around 20 that ran 25% to 900% too…that i dont incude ofcourse cause gotta hit 1,000% or nothing.
Well guys……whoever is here….lets hope OTC is back with all this volume and runners again, and have a great end to 2023 and start 2024 with a bang:
CHAI!
five 2021 1,000% gainers - and then none for 2022 lol….worst two year stretch in OTC ive seen since about 2001 when got in. SEC shut down but we may be turning a corner back to somewhat normal here in late 2023…..we shall see!:
CCTL .004 to .04+
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160769749
VPER .0013 to .04+
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161166405
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160862088
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161181081
DSCR .003 to .03+
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161220721
APYP .007 to .10+
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161899497
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161902047
GGII .01 to .10+
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163522704
…thanks brotha, hoping SONG would have held today cause its great news. And BEGI is just unreal the more i DD.
Ok have a good nite…OTC on verge of breaking out like at least 2017 or so!
Two Awesome Calls BEGI & SONG! Both are up Big from your alert! Congratulations and Keep them Coming!!!
Rigatoni who I trust very much on the pennies thinks NHMD is solid! He Believes The Deal is Real!
I have done my own DD and I feel everything checks out. At .0018 definitely worth the gamble.
I took a starter on SONG which is tough to fill? Must have a tiny float? I took out the .0013's.
I also took a starter on BEGI @ .0011.
I thank you for the heads up!
…wow ok thanks for heads up was wondering about that one-!
Thanks for the heads up! Checking both of them out! Don't miss NHMD for it's merger which is scheduled to close tomorrow October 31st.
…hey brotha….maybe OTC waking up a bit? I like:
SONG and BEGI.
SONG has massive revs for a penny stock and CEO is doing everything right lately:
Condemning pro-Hamas rallies on American college campuses by increasing their music royalty fees up millions….to those campuses where the rallies are…..and just that PR last Friday so bold……first public company to do this?
And for DD i found PennyWhale on Twitter has real good DD..check it out.:
https://twitter.com/WhalePenny
Price is now .0012 but i called it on BBs board Friday at .0008…
i wanted to see if something would run more then a day to post here, lol
The second stock that really has my interest is @.0011 now……: BEGI. They said a Patent should be issued in November in regards to technology trading software/platform that gives them next 20 years protection for trading stocks on blockchain…..which isnt this a yuuuge deal? With GVSI a blockchain rumored RM coming up …now running wild……i think The Market will look for any legit other micro penny stocks in the field….and then they will find with wide eyes BEGI.
So i need to do more DD on BEGI but got a good starter and looking to buy any shares under .001 if possible.
Ok thats it lets see if OTC wakes up and we can all have fun again!
Same here my Friend!
…SMME @.001, another truly disruptive new tech thats been developed for years and millions in RD. Here are more recent PRs…connecting dots looks like they are finally, after all these years, going to have working prototype to show their claimed ‘large bank’…..just Prd that Visa and MasterCard starting adopting this…..as this obviously would be safest way…..finger print on credit card…and SMME has the Patents and also only one that detects lol ‘live finger’……so IF they can slow the dilution and IF card comes out sooner then later…boom!:
SmartMetric Welcomes the Adoption of Biometric Credit Cards by Both Visa and MasterCard
NEW YORK--(BUSINESS WIRE)-- SmartMetric, Inc. (OTC: SMME) recognizing the advanced security features of credit cards with built in biometric recognition technology both Visa2 and MasterCard2 have adopted the use of biometric credit cards over their respective payment networks.
As with any new disruptive technology, SmartMetric sees that in the first instance there will be a steady adoption take up and then we will see a dramatic S-curve adoption of biometric cards as banks and consumers alike are drawn to the advanced security of credit cards that have inbuilt biometrics.
“SmartMetric is the original developer of biometric credit cards and having spent literally years and millions of dollars in R&D to reduce the size of biometric electronics to fit inside a credit card, finds that it has created the most advanced and user-friendly biometric credit card in the world," said SmartMetric’s President and CEO, Chaya Hendrick.
“SmartMetric leads the world in biometric credit card technology in having developed a biometric credit card that has an internal rechargeable battery that is used to power the fingerprint scanning of the card user, independent of card reading terminals and ATMs. This allows the SmartMetric biometric card to be used “anywhere and anytime” a card holder wants to use their new biometric card.
Other less advanced cards have begun trials in Europe that are not self-powered. This is a huge disadvantage over the SmartMetric card as a non-powered biometric card will not work at a lot of gas stations, ATMs and restaurants that process the credit card charging away from the table.
The advanced SmartMetric biometric card has many other features, not least is its hardware-based detection of a live finger. This provides the card with added security against fake fingerprint replicas, making the SmartMetric biometric card the most secure card developed.”
https://www.otcmarkets.com/stock/SMME/news/story?e&id=2561800
SmartMetric Uses Issued Design Patents to Block Any Other Biometric Fingerprint Activated Cards in the United States
SmartMetric, Inc. (OTC: SMME) having spent over a decade on research and development in creating a credit card with an inbuilt fingerprint scanner for the ultimate in credit card security. SmartMetric has protected its invention of a biometric fingerprint activated credit card with patents.
As the company moves ever closer to releasing its biometric credit card in association with credit card issuing banks, a few copy cat companies have emerged to attempt to compete in the over 11 billion unit issued global card market.
The founder and inventor of SmartMetric Chaya Hendrick, realizing the enormity of the invention of a credit card with built inside the card fingerprint recognition for card security, early on applied for patents that would then be made available to SmartMetric so as to protect its position as the original and first developer of biometric activated credit cards.
"Without a doubt our strongest patents that basically stop any one else from selling any type of card with a smartcard chip on it and a fingerprint sensor, are the issued design patents," said SmartMetric's President & CEO, Chaya Hendrick.
The issued design patents cover various shapes of fingerprint sensors that can be placed on the surface of the card in any place that on the card that a sensor can be placed. Effectively stopping anyone else from having a smart card with a chip and sensor on it or a credit card with a chip and fingerprint sensor from on it from being sold in the largest credit card market in the world which is the United States.
These multiple United States Patent Office issued design patents, give SmartMetric an unassailable product monopoly position in the US market for fingerprint activated biometric credit cards.
"Unlike other types of patents, design patents are the easiest to enforce as they do not require years of Federal Court litigation to enforce. Basically, all we need to do is take the issued design patents to the pertinent Government department and have competitors copycat cards seized at port of entry or within the USA at any office or warehouse," said Chaya Hendrick.
SmartMetric is in the final stages of QC testing of its biometric card hardware along with the biometric card internal software and embedded operating system. This is the final preparation of the SmartMetric biometric card product prior to presenting it to one of the World's largest credit card brands and card networks. It is planned that then the card will be offered to various major card issuing banks globally.
"We know it has been a long develpment process and that many banks are wanting to have in hand our advanced biometric card however we are diligently testing our final product to ensure that when it goes live with issuing banks that it will be a fail-safe product. After years of R&D we are extremely excited to have our reached this final stage of our biometric card product," said Chaya Hendrick
According to independent research nearly 70% of existing credit card holders would freely pay $70 dollars for a biometric secured credit card in order to protect themselves from fraud.”
https://www.tmcnet.com/usubmit/2023/06/19/9834951.htm
NEWS: SmartMetric Advises It Has Completed Electronic Assembly of Its New Biometric Card
NEW YORK, April 17, 2023--(BUSINESS WIRE)--SmartMetric, Inc. (OTC: SMME) has completed the electronic assembly of its new biometric card. The card is now being shipped to its engineering center to have the card's software, including the card's operating system, fingerprint sensing software and the card's advanced power management software, installed.
SmartMetric has separated its software from its electronic assembly process to add greater protection for its specialized and highly valuable software.
Following the card's software integration and final printing lamination SmartMetric will be presenting its card to a major global credit card payments network for final testing and approval for use of the card on the network worldwide.
Once network testing is completed, SmartMetric will then be making its card available to certain banks who are motivated to introduce the SmartMetric advanced biometric card to its credit card customers. Being an advanced new credit card offering the banks are looking at using the card to not only assist in the ongoing battle against credit card fraud but to have the card win them new customers who are attracted to using a biometric protected card for their daily credit card use.
What we have created is arguably the most advanced biometric secured credit card ever developed, a card that is designed to work at all card readers and allow mass credit card issuers to send the card to their customers for at home fingerprint in-card enrollment," said SmartMetric’s President and CEO, Chaya Hendrick.
Other less advanced biometric cards require the user to go into a bank and use a special reader to enroll their fingerprint onto a card. These basic cards also do not have their own power source but rather require the card to be held while in a credit card reader. This makes them unable to work in most ATMs, gas pumps and restaurants.
"There is nothing that comes near the advanced level of the SmartMetric biometric credit card," said Chaya Hendrick.
The SmartMetric card also has a new hardware feature built inside that detects whether or not the fingerprint touching the card's sensor is in fact a live person or say a silicon replica of a fingerprint. No other biometric card on the market has this feature. Rather they say they are using software to achieve live detection; however, our own engineering testing has shown that software cannot adequately achieve proper fingerprint detection discernment between a fake fingerprint and a live fingerprint.
"Our card is in our opinion the most advanced biometric credit card to be made. It is also protected by issued patents in the USA that will allow us to file injunctions against copycats who want to copy what we have spent years in developing," said Chaya Hendrick.
Patents have also been filed in accordance with the Hague convention internationally.
According to figures released by the credit card standards body EMVco more than 11 billion EMV Chip cards have now been issued by financial institutions around the world. The SmartMetric biometric technology works with these EMV chips and existing chip card readers and ATMs. “
https://www.otcmarkets.com/stock/SMME/news/SmartMetric-Advises-It-Has-Completed-Electronic-Assembly-of-Its-New-Biometric-Card?id=396854
SmartMetric Welcomes The Announced End Of The Credit Card Mag Stripe With It Being Replaced By Fingerprint Biometric Cards
Press Release | 04/21/2023
SmartMetric, Inc. (OTC: SMME) – It is reported that Spain is the first European country that has officially announced the adoption of fingerprint activated biometric credit and debit cards that will not have a mag stripe.
https://www.otcmarkets.com/stock/SMME/news/SmartMetric-Welcomes-The-Announced-End-Of-The-Credit-Card-Mag-Stripe-With-It-Being-Replaced-By-Fingerprint-Biometric-Car?id=397507
SMME SECURITY DETAILS
Share Structure
Market Cap calculated only for this class of securities.
Market Cap
1,936,409
06/22/2023
Authorized Shares
5,000,000,000
06/16/2023
Outstanding Shares
1,936,408,660
06/16/2023
Restricted
426,357,706
06/16/2023
Unrestricted
1,510,050,954
06/16/2023
Held at DTC
1,367,261,741
06/16/2023
Float
257,639,859
02/02/2022
Par Value
0.001
https://www.otcmarkets.com/stock/SMME/security
Followers
|
52
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
452
|
Created
|
12/27/18
|
Type
|
Free
|
Moderator JohnnyRothrock | |||
Assistants |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |